<DOC>
	<DOCNO>NCT02579044</DOCNO>
	<brief_summary>This phase I/II dose-escalation trial everolimus combination lonafarnib Hutchinson-Gilford Progeria Syndrome ( HGPS ) progeroid laminopathies ( henceforth `` progeria '' ) . The study conduct single clinical site utilizing Clinical Translational Study Unit ( CTSU ) Boston Children 's Hospital . Lonafarnib administer dose previously establish pediatric population population progeria subject . This study first determine dose-limiting toxicity ( DLT ) maximum tolerate dose ( MTD ) everolimus administer combination lonafarnib . It determine efficacy everolimus administer MTD combination lonafarnib disease progeria .</brief_summary>
	<brief_title>Phase I/II Trial Everolimus Combination With Lonafarnib Progeria</brief_title>
	<detailed_description />
	<mesh_term>Progeria</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Geneticallyconfirmed progeria . display clinical sign progeria per clinical trial team . currently receive lonafarnib protocol 09060298 experience grade 3 4 toxicity within two month precede enrollment willing able come Boston appropriate study examination . recent fracture major surgery ( within four week ) Absolute poly count ( Absolute neutrophil count + band + monocyte ) &gt; 1,000/uL platelet &gt; 75,000/uL ( transfusion independent ) hemoglobin &gt; 9 g/dL creatinine ≤ 1.5 time upper limit normal ( ULN ) age Glomerular filtration rate ( GFR ) &gt; 70 mL/min/1.73m2 bilirubin ≤ 1.5x upper limit normal age SGPT ( ALT ) &lt; SGOT ( AST ) ≤ 2.5x normal range age serum albumin great equal 2 g/dL PT/PTT : INR &lt; 1.3 ( &lt; 3 anticoagulant ) Fasting LDL cholesterol within 1.5x ULN per institutional guideline ( ie , &lt; 195 mg/dL 2 18 year age , &lt; 240 mg/dL subject &gt; 18 year old ) * Fasting serum cholesterol &lt; 300 mg/dL ( &lt; 7.75 mmol/L ) * Fasting triglyceride &lt; 2.5 ULN ( &lt; 325 mg/dL age 2 18 , &lt; 400 age &gt; 18 ) * *may reevaluate eligibility initiation lipidlowering therapy Signed informed consent accord institutional guideline must obtain subject must begin therapy within twentyeight ( 28 ) day . Other drug use protocol , drug target treat progeria exclude . Drugs treat symptom progeria permit . Subjects must take medication significantly affect metabolism lonafarnib Subjects receive chronic , systemic treatment corticosteroid another immunosuppressive agent . Subjects endocrine deficiency allow receive physiologic stress dose steroid necessary . Topical inhale steroid allow . Subjects major surgery significant traumatic injury within 4 week start study drug ; recover side effect major surgery ( define require general anesthesia exclude procedure insertion central venous access ) ; may require major surgery course study . 13.2.5 Subjects active bleeding diathesis oral antivitamin K medication ( except low dose coumadin ) . Subjects severe and/or uncontrolled medical condition condition could affect participation study : know severely impaired lung function active ( acute chronic ) uncontrolled severe infection . liver disease cirrhosis , chronic active hepatitis chronic persistent hepatitis . History hepatitis B hepatitis C Other concurrent severe and/or uncontrolled medical disease could compromise participation study ( i.e. , uncontrolled diabetes , uncontrolled hypertension , severe infection , severe malnutrition , chronic liver renal disease , active upper GI tract ulceration ) . A known history Human Immunodeficiency Virus ( HIV ) seropositivity know immunodeficiency . Impairment gastrointestinal function gastrointestinal disease may significantly alter absorption everolimus ( e.g. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome small bowel resection ) . A nasogastric tube ( NG tube ) gastric tube ( G tube ) allow . Subjects know suspected hypersensitivity excipients include formulation treat . Subjects must pregnant breastfeeding . Female subject childbearing potential must negative serum urine pregnancy test . Sexually active male female subject reproductive potential must agree use medically accept form birth control study 10 week treatment . It permissible female subject take oral contraceptive hormonal method receive treatment everolimus .</criteria>
	<gender>All</gender>
	<minimum_age>18 Months</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>